740
Views
5
CrossRef citations to date
0
Altmetric
STEM CELL TRANSPLANTATION

Reduced-intensity stem cell allografting for PNH patients in the eculizumab era: The Mexican experience

, , , , , & show all

References

  • Parker CJ, Omine M, Richards S, Nishimura J, Bessler M, Ware R, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106(12):3699–709.
  • Parker CJ. Paroxysmal nocturnal hemoglobinuria. Curr Opin Hematol. 2012;19(3):141–8.
  • Endo M, Beatty PG, Vreeke TM, Wittwer C, Singh SP, Parker CJ. Syngeneic bone marrow transplantation without conditioning in a patient with paroxysmal nocturnal hemoglobinuria: in vivo evidence that the mutant stem cells have a survival advantage. Blood. 1996;88(2):742–50.
  • Ditschkowski M, Trenschel R, Kummer G, Elmaagacil AH, Beelen DW. Allogeneic CD34-enriched peripheral blood stem cell transplantation in a patient with paroxysmal nocturnal haemoglobinuria. Bone Marrow Transplant. 2003;32(6):633–5.
  • Brodsky RA. Stem cell transplantation for paroxysmal nocturnal hemoglobinuria. Haematologica. 2010;95(6):855–6.
  • Santarone S, Bacigalupo A, Risitano AM, Tagliaferri E, Di Bartolomeo E, Iori AP, et al. Hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: long-term results of a retrospective study on behalf of the Gruppo Italiano Midollo Osseo (GITMO). Haematologica. 2012;95(6):983–8.
  • Risitano AM, Rotoli B. Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents. Biologics. 2008;2(2):205–22.
  • Lee JW, Jang JH, Kim JS, Yoon SS, Lee JH, Kim YK, et al. Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry. Int J Hematol. 2013;97(6):749–57.
  • Sutherland DR, Kuek N, Davidson J, Barth D, Chang H, Yeo E, et al. Diagnosing PNH with FLAER and multiparameter flow cytometry. Cytometry B Clin Cytom. 2007;72(3):167–77.
  • Preis M, Lowrey CH. Laboratory test for paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2014;89(3):339–41.
  • Peffault de Latour R, Schrezenmeier H, Bacigalupo A, Blaise D, de Souza CA, Vigouroux S, et al. Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria. Haematologica. 2012;97(11):1666–73.
  • Ruiz-Argüelles GJ, Hernández-Reyes J, González-Ramírez MP, Martagón-Herrera NA, Rosales-Durón AD, Ruiz-Delgado GJ. Paroxysmal nocturnal hemoglobinuria in México: a 30-year, single institution experience. Rev Invest Clin. 2014;66(1):12–6.
  • Ruiz-Argüelles GJ, Morales-Aceves R, Labardini J, Kraus-Weisman A. Hemoglobinuria paroxística nocturna. Experiencia de 30 años en el Instituto Nacional de la Nutrición (México). Sangre (Barc). 1981;26:463–70.
  • Góngora-Biachi R, González-Martinez P, Gonzalez-Llaven J, Delgado-Lamas J, Silva-Moreno M, Rico-Bazaldúa G. Clinical spectrum and prognostic factors in paroxysmal nocturnal hemoglobinuria in Mexico. Rev Invest Clin. 1994;46 (suppl 1):187.
  • Kelly RJ, Hill A, Arnold LM, Brooksbank GL, Richards SJ, Cullen M, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117(25):6786–92.
  • de Latour RP, Mary JY, Salanoubat C, Terriou L, Etienne G, Mohty M, et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood. 2008;112(8):3099–106.
  • Sharma V. Paroxysmal nocturnal hemoglobinuria: pathogenesis, testing and diagnosis. Clin Adv Hematol Oncol. 2013;11(9):1–11.
  • Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A, González-Llano O, Cantú OE, Hernández NE. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis. Bone Marrow Transplant. 2000;25:131–3.
  • Ruiz-Delgado GJ, Ruiz-Argüelles GJ. A Mexican way to cope with stem cell transplantation. Hematology. 2012;17 (Suppl 1):195–7.
  • Galo-Hooker E, Ruiz-Delgado GJ, Zamora-Ortiz G, Velázquez-Sánchez-de-Cima S, Ruiz-Argüelles GJ. In pursuit of the graft versus myeloma effect: a single institution experience. Hematology. 2013;18:89–92.
  • Kaplan EL, Meier P. Nonparametric estimations from incomplete observations. J Am Stat Assoc. 1958;53:457–63.
  • Ruiz-Argüelles GJ, Ruiz-Delgado GJ, Calderón-Meza E, Ruiz-Argüelles A, Garcés-Eisele J. Donor-derived hairy cell leukemia. Leukemia Lymph. 2009;50:1712–4.
  • Ruiz-Arguelles GJ. Whither the bone marrow transplant. Hematology. 2010;15:1–3.
  • Ruiz-Argüelles GJ, Tarín-Arzaga LC, González-Carrillo ML, Gutiérrez-Riveroll KI, Rangel-Malo R, Gutiérrez-Aguirre CH, et al. Therapeutic choices in patients with Ph1 (+) chronic myelogenous leukemia living in México in the tyrosine kinase inhibitors (TKI) era: stem cell transplantation or TKI′s? Bone Marrow Transplant. 2008;42:23–8.
  • López-Otero A, Ruiz-Delgado GJ, Ruiz-Argüelles GJ. A simplified method for stem cell autografting in multiple myeloma: a single institution experience. Bone Marrow Transplant. 2009;44:715–9.
  • Gómez-Almaguer D, Vela-Ojeda J, Jaime-Pérez JC, Guitiérrez-Aguirre CH, Cantú-Rodríguez OG, Sobrevilla-Calvo P, et al. Allografting in patients with severe aplastic anemia using peripheral blood stem cells and a fludarabine-based conditoning regimen: the Mexican Experience. Am J Hematol. 2006;81:157–61.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.